SCHEMBL3077036

SCHEMBL3077036

CN(C)S(=O)(=O)c1ccc(-c2ccc(N)c(Br)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
PKM P14618 2/20 0.53
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.53
KMT2A Q03164 1/20 0.53
CA12 O43570 4/20 0.51
CA2 P00918 4/20 0.51
CA9 Q16790 4/20 0.51
CA1 P00915 2/20 0.51
CA4 P22748 1/20 0.51
CA6 P23280 1/20 0.51
CA5A P35218 1/20 0.51
CA7 P43166 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
MAPT P10636 1/20 0.50
LMNA P02545 5/20 0.43
HTT P42858 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10693083 0.90 CA1 (0.63) ALDH1A1PKMMEN1POLBKMT2A
SCHEMBL14392179 0.85 CA2 (0.46) ALDH1A1PKMMEN1POLBKMT2A
SCHEMBL3909923 0.83 SMN1; SMN2 (0.65) ALDH1A1POLBCA12CA2CA9
SCHEMBL5890969 0.78 LMNA (0.64) ALDH1A1PKMKMT2ACA12CA2
SCHEMBL5891165 0.78 LMNA (0.64) ALDH1A1PKMKMT2ACA12CA2
SCHEMBL5623940 0.78 ALDH1A1 (0.60) ALDH1A1PKMMEN1POLBKMT2A
SCHEMBL914479 0.77 ALDH1A1 (0.64) ALDH1A1PKMMEN1POLBKMT2A
SCHEMBL3082587 0.77 CA12 (0.57) ALDH1A1PKMMEN1POLBKMT2A
SCHEMBL1503404 0.74 KMT2A (0.55) ALDH1A1MEN1POLBKMT2ACA12
SCHEMBL7933846 0.73 ALDH1A1 (0.58) ALDH1A1PKMMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER ALDH1A1 4731/4885PKM 792/4885MEN1 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.